Brigade Enterprises Limited (NSE:BRIGADE)
India · Delayed Price · Currency is INR 968.70
-24.10 (-2.43%)
Aug 6, 2025, 3:29 PM IST
Theseus Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 50,742 | 48,967 | 34,446 | 29,988 | 19,500 | Upgrade | |
Revenue Growth (YoY) | 3.62% | 42.16% | 14.87% | 53.79% | -25.92% | Upgrade |
Cost of Revenue | 24,491 | 28,274 | 18,493 | 16,374 | 10,907 | Upgrade |
Gross Profit | 26,251 | 20,693 | 15,954 | 13,614 | 8,593 | Upgrade |
Selling, General & Admin | 5,153 | 3,921 | 3,311 | 2,586 | 1,826 | Upgrade |
Other Operating Expenses | 6,898 | 4,777 | 4,021 | 3,332 | 2,035 | Upgrade |
Operating Expenses | 14,945 | 11,738 | 10,483 | 9,424 | 6,234 | Upgrade |
Operating Income | 11,306 | 8,955 | 5,471 | 4,190 | 2,359 | Upgrade |
Interest Expense | -4,827 | -4,736 | -4,171 | -4,306 | -3,376 | Upgrade |
Interest & Investment Income | 1,948 | 1,189 | 781.1 | 337.2 | 296.5 | Upgrade |
Earnings From Equity Investments | - | - | 41 | 27 | 25.7 | Upgrade |
Currency Exchange Gain (Loss) | -5.5 | -2.9 | -5.8 | -1.3 | -9.3 | Upgrade |
Other Non Operating Income (Expenses) | 150.2 | 263 | 18.6 | 33.7 | 64.8 | Upgrade |
EBT Excluding Unusual Items | 8,572 | 5,669 | 2,135 | 280.6 | -639.3 | Upgrade |
Gain (Loss) on Sale of Investments | 104.4 | 37.4 | 369.4 | 135.4 | -398.5 | Upgrade |
Gain (Loss) on Sale of Assets | 16.3 | -19.5 | 8.3 | 0.2 | 149.6 | Upgrade |
Asset Writedown | - | - | 170 | -193.2 | -185 | Upgrade |
Other Unusual Items | - | - | 97.2 | -373.4 | -177.8 | Upgrade |
Pretax Income | 8,693 | 5,687 | 2,780 | -150.4 | -1,251 | Upgrade |
Income Tax Expense | 1,888 | 1,676 | 558.2 | 497.2 | -286.9 | Upgrade |
Earnings From Continuing Operations | 6,805 | 4,010 | 2,222 | -647.6 | -964.1 | Upgrade |
Minority Interest in Earnings | 52.9 | 505.7 | 692.4 | 1,475 | 500.9 | Upgrade |
Net Income | 6,858 | 4,516 | 2,914 | 827.7 | -463.2 | Upgrade |
Net Income to Common | 6,858 | 4,516 | 2,914 | 827.7 | -463.2 | Upgrade |
Net Income Growth | 51.85% | 54.97% | 252.07% | - | - | Upgrade |
Shares Outstanding (Basic) | 239 | 231 | 231 | 226 | 207 | Upgrade |
Shares Outstanding (Diluted) | 239 | 232 | 231 | 226 | 207 | Upgrade |
Shares Change (YoY) | 3.28% | 0.17% | 2.21% | 9.33% | 0.44% | Upgrade |
EPS (Basic) | 28.74 | 19.56 | 12.64 | 3.67 | -2.24 | Upgrade |
EPS (Diluted) | 28.68 | 19.51 | 12.61 | 3.66 | -2.24 | Upgrade |
EPS Growth | 47.00% | 54.72% | 244.54% | - | - | Upgrade |
Free Cash Flow | 3,559 | 654.3 | 6,438 | 8,236 | 3,075 | Upgrade |
Free Cash Flow Per Share | 14.89 | 2.83 | 27.86 | 36.43 | 14.87 | Upgrade |
Dividend Per Share | 2.500 | 2.000 | 2.000 | 1.500 | 1.200 | Upgrade |
Dividend Growth | 25.00% | - | 33.33% | 25.00% | 20.00% | Upgrade |
Gross Margin | 51.73% | 42.26% | 46.31% | 45.40% | 44.07% | Upgrade |
Operating Margin | 22.28% | 18.29% | 15.88% | 13.97% | 12.10% | Upgrade |
Profit Margin | 13.51% | 9.22% | 8.46% | 2.76% | -2.38% | Upgrade |
Free Cash Flow Margin | 7.01% | 1.34% | 18.69% | 27.46% | 15.77% | Upgrade |
EBITDA | 14,177 | 11,963 | 8,559 | 7,642 | 4,669 | Upgrade |
EBITDA Margin | 27.94% | 24.43% | 24.85% | 25.48% | 23.94% | Upgrade |
D&A For EBITDA | 2,871 | 3,008 | 3,088 | 3,452 | 2,309 | Upgrade |
EBIT | 11,306 | 8,955 | 5,471 | 4,190 | 2,359 | Upgrade |
EBIT Margin | 22.28% | 18.29% | 15.88% | 13.97% | 12.10% | Upgrade |
Effective Tax Rate | 21.72% | 29.48% | 20.08% | - | - | Upgrade |
Revenue as Reported | 53,135 | 50,642 | 35,632 | 30,655 | 20,104 | Upgrade |
Advertising Expenses | 1,057 | 684.9 | 600.6 | 501.5 | 300.7 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.